|
|
BLP |
|
Vaxjo ID |
493 |
|
Vaccine Adjuvant Name |
BLP |
|
Adjuvant VO ID |
VO_0005770
|
|
Description |
vaccine adjuvant that induces Th1/Th17 balanced response |
|
Stage of Development |
Research |
|
Location Licensed |
Netherlands |
|
Host Species for Testing |
Mouse |
|
Appearance |
shape and size of untreated bacterium |
|
Storage |
-80C |
|
Preparation |
acid pre-treatment, which degrades all cellular components, including DNA and proteins but leaves the peptidoglycan shell intact |
|
Function |
Type: particulate antigen delivery system vaccine adjuvant. Target Receptor: Toll-like receptor 2 (TLR2). Induces Th1/Th17 mixed immune profile. TLR2 agonist that drives dendritic cell activation and Th1/Th17 polarization |
| References |
Keijzer et al., 2014: Keijzer C, Haijema BJ, Meijerhof T, Voorn P, de Haan A, Leenhouts K, van Roosmalen ML, van Eden W, Broere F. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion. Vaccine. 2014; 32(24); 2904-2910. [PubMed: 24598720].
|
|
